Angiolab Statistics
Total Valuation
Angiolab has a market cap or net worth of KRW 13.13 billion.
Market Cap | 13.13B |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Angiolab has 3.28 million shares outstanding.
Current Share Class | 3.28M |
Shares Outstanding | 3.28M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 36.81% |
Owned by Institutions (%) | n/a |
Float | 1.86M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 18.68 |
PB Ratio | 3.69 |
P/TBV Ratio | 4.46 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.72
Current Ratio | 6.72 |
Quick Ratio | 6.05 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -775.80 |
Financial Efficiency
Return on equity (ROE) is -28.58% and return on invested capital (ROIC) is -10.05%.
Return on Equity (ROE) | -28.58% |
Return on Assets (ROA) | -8.55% |
Return on Invested Capital (ROIC) | -10.05% |
Return on Capital Employed (ROCE) | -18.00% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.13 |
Inventory Turnover | 1.29 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.21% in the last 52 weeks. The beta is 0.14, so Angiolab's price volatility has been lower than the market average.
Beta (5Y) | 0.14 |
52-Week Price Change | -44.21% |
50-Day Moving Average | 4,283.10 |
200-Day Moving Average | 6,281.60 |
Relative Strength Index (RSI) | 40.17 |
Average Volume (20 Days) | 856 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Angiolab had revenue of KRW 702.62 million and -1.19 billion in losses. Loss per share was -1,356.00.
Revenue | 702.62M |
Gross Profit | 338.60M |
Operating Income | -716.07M |
Pretax Income | -1.19B |
Net Income | -1.19B |
EBITDA | -483.63M |
EBIT | -716.07M |
Loss Per Share | -1,356.00 |
Balance Sheet
The company has 2.49 billion in cash and n/a in debt, giving a net cash position of 2.49 billion or 757.45 per share.
Cash & Cash Equivalents | 2.49B |
Total Debt | n/a |
Net Cash | 2.49B |
Net Cash Per Share | 757.45 |
Equity (Book Value) | 3.56B |
Book Value Per Share | 3,675.78 |
Working Capital | 2.40B |
Cash Flow
In the last 12 months, operating cash flow was -82.73 million and capital expenditures -22.57 million, giving a free cash flow of -105.30 million.
Operating Cash Flow | -82.73M |
Capital Expenditures | -22.57M |
Free Cash Flow | -105.30M |
FCF Per Share | -32.09 |
Margins
Gross margin is 48.19%, with operating and profit margins of -101.91% and -168.87%.
Gross Margin | 48.19% |
Operating Margin | -101.91% |
Pretax Margin | -168.87% |
Profit Margin | -168.87% |
EBITDA Margin | -68.83% |
EBIT Margin | -101.91% |
FCF Margin | n/a |
Dividends & Yields
Angiolab does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -9.04% |
FCF Yield | -0.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Angiolab has an Altman Z-Score of -0.27 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.27 |
Piotroski F-Score | 1 |